Boehringer Ingelheim India and NIPER Hajipur Sign MoU to Strengthen Pharmaceutical Research

manufacturing-news
Image Courtesy: Boehringer Ingelheim

Boehringer Ingelheim India Private Limited and the National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, have entered into a five-year Memorandum of Understanding (MoU) to promote collaboration in pharmaceutical research, education, and innovation. The partnership is designed to create new opportunities for students and researchers across Bihar and eastern India, while strengthening India’s pharmaceutical talent ecosystem.

The MoU was signed at the Department of Pharmaceuticals in the presence of Manoj Joshi (IAS), Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers. Dr Kinny Singh (IAS), Deputy Secretary, and Prof K Ruckmani, Director of NIPER Hajipur, were also present on the occasion. The agreement establishes a structured framework for collaboration across key areas including advanced pharmaceutical technologies, novel drug delivery systems, joint research programmes, academic exchange, and capability development initiatives.

As part of the collaboration, Boehringer Ingelheim will provide researchers and faculty at NIPER Hajipur access to opnMe®, its global open science platform. The portal offers scientists access to well-characterised pre-clinical compounds at no cost for research purposes. With more than 150 molecules already shared with Indian institutions, this initiative extends access to eastern India at a larger scale, enabling researchers to work with globally validated tools and resources.

The partnership aligns with the Government of India’s Viksit Bharat vision and the Biopharma SHAKTI initiative announced in the Union Budget 2026–27. This national programme aims to position India as a leader in innovation-led biopharmaceutical development, with NIPER institutions playing a central role as hubs of excellence in translational research and talent development.

Speaking at the event, Shri Joshi highlighted the importance of industry-academia collaboration in bridging the gap between research and commercial application. He noted that India’s pharmaceutical sector is undergoing a transition toward a value-driven, innovation-focused model supported by policy initiatives, infrastructure development, and stronger partnerships.

Prof Ruckmani stated that the collaboration will enhance research capabilities at NIPER Hajipur and provide students with exposure to global research practices. Meenal Gauri, Managing Director, Boehringer Ingelheim India, emphasized the company’s continued commitment to supporting India’s pharmaceutical education ecosystem and expanding access to open science resources. The collaboration is structured on a non-commercial basis, reflecting a shared focus on ethical research, academic advancement, and public health outcomes.

Boehringer Ingelheim is a global biopharmaceutical company working in human and animal health, with research programmes focused on diseases with high unmet needs. Its India operations support healthcare solutions in areas such as diabetes, cardiovascular disease and respiratory conditions, while also working with partners to advance research and education in the country.